Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Contracts Finder |
| Notice Type: | Award notice |
| Buyer: | Newcastle University |
| Main Category: | Services |
| Procurement Method: | Restricted procedure |
| Tender Status: | Closed |
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
29 July 2022
Closed
Estimated Value
£30,000
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Estimated Value (ex. VAT): | £30,000 |
| Release Date: | 30 September 2022 |
| Application Deadline: | 29 July 2022 |
| Contract Start Date: | 30 September 2022 |
| Contract End Date: | 1 April 2023 |
| Contract Duration: | 6 months |
| Procurement ID (OCID): | ocds-b5fd17-0c8e5c52-a3a5-4d4b-8025-4ccb4ae7b788 |
| Notice Reference: | c970db26-2735-4c93-88b9-5e93b1c281f8-576550 |
All 2 notices for this procurement, oldest first.
(NU/1433-36) IndigoDX Ltd: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation
(NU/1433-36) IndigoDX Ltd: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation
Earlier notices predate the Procurement Act 2023 (commenced 24 Feb 2025) and therefore don't carry UK1–UK17 codes.
View Original Notice
Access the full notice on the official portal
Awarded to
| Award value: | £30,000 |
| Award decision date: | 5 September 2022 |
| Award status: | Active |
1 in 5 adults in the UK suffer from urinary symptoms caused by an overactive bladder (OAB). Symptoms include urgency (a sudden compelling desire to pass urine, which cannot be deferred), increased frequency of voiding (both day and night) and urge incontinence (involuntary leakage accompanied by / immediately preceded by urgency). The Team wishes to establish a spinout company to produce a Dipstick-style test. Our discovery is currently being developed into a simple-to-use diagnostic tool used for (1) regular screening for OAB in adults, at a GP surgery, pharmacy or nursing home, and (2) to assess the effectiveness of treatments (companion diagnostic) and modifying dosing/treatments accordingly. Accurate and early diagnosis will improve treatment outcomes, eliminating the need for patients to have invasive and high-risk surgery-led second-line treatments necessary for advanced-stage disease. Currently there is no competition for a non-invasive biomarker-based test, and new product development activity appears to be very limited, suggesting an opportunity for 'first mover advantage' and to establish a standard. We require a driven executive to take this technology forward and build a compelling proposition for investment. The Executive will need to create a robust business model that is acceptable to the founders, develop and deliver pitch materials for investors and establish collaborative research projects. The executive appointed should have an appropriate background, ideally with experience of high tech starts ups, securing seed investment and establishing manufacturing facilities.